Survivors of breast cancer with an unhealthy metabolic profile—commonly referred to as metabolic syndrome—face a 69% higher ...

NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.